Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)

C. Zhou, Yi‐Long Wu, G. Chen, +19

Annals of Oncology

Non-small-cell Lung CancerMedicinePathologyFirst-line TreatmentCancer Treatment +6

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)

G. Chen, J. Feng, Caicun Zhou, +19

Annals of Oncology

MedicineCancer ManagementPhase IiiPathologyCancer Treatment +4

Predominance of Cryptococcus neoformans var. grubii multilocus sequence type 5 and emergence of isolates with non-wild-type minimum inhibitory concentrations to fluconazole: a multi-centre study in China

Xin Fan, Meng Xiao, S. Chen, +18

Clinical Microbiology and Infection

Diagnostic MycologyMulti-centre StudyPathogenic MicrobiologyMicrobial DiseaseCryptococcus Neoformans +6

Risk factors for lymph node metastasis in papillary thyroid microcarcinoma: Older patients with fewer lymph node metastases

L. Zhang, Jiali Yang, Qianqian Sun, +8

European Journal of Surgical Oncology

Papillary Thyroid MicrocarcinomaMedicineThyroid DiseasePathologyLymph Node Metastasis +5

FP13.04 KEYNOTE-042 3-Year Survival Update: 1L Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ Locally Advanced/Metastatic NSCLC

Byoung Chul Cho, Yi‐Long Wu, G. Lopes, +14

Journal of Thoracic Oncology

Selection of a novel DNA thioaptamer against HER2 structure

Yan Hu, Junwen Duan, Bangrong Cao, +8

Clinical & Translational Oncology

Natural SciencesOligonucleotideDna ReplicationMolecular BiologyNovel Dna Thioaptamer +1

Keynote-407 China Extension study: Pembrolizumab (pembro) plus chemotherapy in Chinese patients with metastatic squamous NSCLC

Ying Cheng, L. Zhang, Jie Hu, +15

Annals of Oncology

MedicineMetastatic Squamous NsclcImmune Checkpoint InhibitorPharmacotherapyCancer Treatment +4

LBA56 ORIENT-12: Sintilimab plus gemcitabine and platinum (GP) as first-line (1L) treatment for locally advanced or metastatic squamous non-small-cell lung cancer (sqNSCLC)

Caicun Zhou, Lin Wu, Yun Fan, +16

Annals of Oncology

MedicineBronchial NeoplasmCancer TreatmentOncologyRadiation Oncology +5

Expression of corticotrophin-releasing hormone and its receptor in patients with intrahepatic cholestasis of pregnancy

Fan Zhou, Mao-mao He, Z.F. Liu, +3

Placenta

Biliary TractPhysiologyCorticotrophin-releasing HormoneGynecologyMaternal Health +4

Expression of urocortin and corticotrophin-releasing hormone receptor-2 in patients with intrahepatic cholestasis of pregnancy

Fan Zhou, L. Zhang, Qiquan Sun, +1

Placenta

Biliary TractPhysiologyGynecologyMaternal HealthCorticotrophin-releasing Hormone Receptor-2 +4